Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

With Ipca Laboratories Limited's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.00000
forwardPE 32.68517
debtToEquity 14.80900
earningsGrowth 0.37900
revenueGrowth 0.09400
grossMargins 0.65304
operatingMargins 0.16239
trailingEps 28.75000
forwardEps 47.85000

Ipca Laboratories Limited's low Debt-to-Equity ratio reflects limited reliance on debt, signaling the company is not over-leveraged. This lower financial risk suggests that Ipca Laboratories Limited has a strong capital structure, which can help sustain long-term stability and attract cautious investors.
Ipca Laboratories Limited's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights Ipca Laboratories Limited's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

The price of Ipca Laboratories Limited has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


There were 1 transactions selling IPCALAB stock, with prevailing market price of 1513.199951171875.1 transactions to buy IPCALAB shares were recorded, with market price at 1189.6500244140625.The ongoing selling activity at IPCALAB's current price levels suggests a potential risk of further declines. If more investors continue to sell, this trend could lead to continued downward pressure on the stock's price.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


The recent buy bias for IPCALAB from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see IPCALAB as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.